Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedNew entries appear in the Study Record Dates showing Results First Submitted (2024-05-13), Results First Submitted that Met QC Criteria (2025-01-07), and Results First Posted (2025-02-03).SummaryDifference0.5%

- Check39 days agoChange Detected- Added a government operating status notice and a version bump to v3.2.0. - Removed the old version tag v3.1.0.SummaryDifference4%

- Check47 days agoChange DetectedAdded new oncology-related terms and upgraded revision to v3.1.0; removed the Liver Cancer topic and old v3.0.2 revision.SummaryDifference1%

- Check61 days agoChange DetectedUpdated to Revision: v3.0.2. Removed the Back to Top element.SummaryDifference0.2%

- Check68 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check75 days agoChange DetectedThe web page has added significant information regarding a facility name, location, and relevant publications related to liver cancer and pembrolizumab, while removing various location terms and resources previously listed.SummaryDifference8%

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.